In Vitro Study To Evaluate the Bioactivity of Freezing a Heparin-Based Dalbavancin Lock Solution-Reference-Cited by-同舟云学术

In Vitro Study To Evaluate the Bioactivity of Freezing a Heparin-Based Dalbavancin Lock Solution

Published:2020-11-17 Issue:12 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Rubia Marta¹,Cordero Andrea²,Pérez-Granda María Jesús³⁴⁵,Cercenado Emilia³⁶,Pascual Cristina⁷,Muñoz Patricia³⁴⁵⁶^ORCID,Guembe María³⁴^ORCID

Affiliation:

1. Biology Department, School of Biology, Universidad Complutense de Madrid, Madrid, Spain

2. Biology Department, School of Biology, Universidad Autónoma de Madrid, Madrid, Spain

3. Department of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain

4. Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

5. CIBER Enfermedades Respiratorias-CIBERES (CB06/06/0058), Madrid, Spain

6. Medicine Department, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain

7. Hematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Abstract

The use of dalbavancin as a catheter lock solution must be addressed in depth before implementation in clinical practice. We assessed whether a heparin-based dalbavancin lock solution could be frozen in single-dose vials for 6 months without affecting its bioactivity against biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Over 6 months, we tested the bioactivity of a frozen solution of dalbavancin (≈1 mg/ml) plus heparin (60 IU) in terms of CFU counts and metabolic activity against biofilms of Staphylococcus aureus ATCC 43300 (MRSA) and Staphylococcus epidermidis ATCC 35984 (MRSE).

Funder

MEC | Instituto de Salud Carlos III

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01495-20

Reference27 articles.

1. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic

2. Espectro antimicrobiano de dalbavancina. Mecanismo de acción y actividad in vitro frente a microorganismos Gram positivos

3. Origin, structure, and activity in vitro and in vivo of dalbavancin